The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
Background: Tyrosine-kinase inhibitors (TKIs) and immunotherapy represent the backbone treatment for metastatic renal cell carcinoma (mRCC) patients. The aim of the present study was to describe mean corpuscular volume (MCV) and red cell distribution width (RDW) in mRCC patients treated with pazopan...
Main Authors: | Chiara Tommasi, Giulia Scartabellati, Diana Giannarelli, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Sebastiano Buti |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-07-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/17562872231187216 |
Similar Items
-
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
by: Giulia Mazzaschi, et al.
Published: (2023-07-01) -
Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
by: Melissa Bersanelli, et al.
Published: (2023-01-01) -
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
by: Carlo Cattrini, et al.
Published: (2022-03-01) -
Association of metallothionein 2A rs10636 with low mean corpuscular volume (MCV), low mean corpuscular haemoglobin (MCH) in healthy Taiwanese
by: Rong-Fu Chen, et al.
Published: (2023-01-01) -
Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
by: Matteo Bauckneht, et al.
Published: (2021-03-01)